Neither tamoxifen nor aromatase inhibitors increase the risk of Parkinson disease in the UK Biobank cohort.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 35442525.
- Also identified by DOI 10.1002/cncr.34245 and PMC identifier 9262755.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Treatment with aromatase inhibitors (AIs) or tamoxifen does not increase the risk of Parkinson’s Disease (PD) in women with breast cancer. The insignificant increase in PD associated with AIs on univariate analysis is an age effect, that is, older women are more likely to receive AIs and more likely to develop PD.
Medical subject headings
- Breast Neoplasms
- Parkinson Disease